“ú–{–òŠw‰ï ‘æ136”N‰ïi‰¡•lj@2016”N3ŒŽ26“ú(“y)E27“ú(“ú)E28“ú(ŒŽ)E29“ú(‰Î)@–k—¢‘åŠw–òŠw•” Œö‰vŽÐ’c–@l “ú–{–òŠw‰ï Œö‰vŽÐ’c–@l “ú–{–òŠw‰ï Œö‰vŽÐ’c–@l “ú–{–òŠw‰ï FAQ

3ŒŽ29“ú(‰Î)@13:15`14:15@F‰ïê ƒpƒVƒtƒBƒR‰¡•l@‰ï‹cƒZƒ“ƒ^[@3F@311+312
IS01
ƒhƒCƒc–òŠw‰ï‘ã•\ŽÒu‰‰
Special Lectures by DPhG Representatives
ƒI[ƒKƒiƒCƒU[F‘¾“c –΁A‘åûü Í

IS01-1
Raising the Gold Standard: Novel Bioisosteric Hinge-Binding Motifs for Tofacitinib-Derived JAK3 Inhibitors
Raising the Gold Standard: Novel Bioisosteric Hinge-Binding Motifs for Tofacitinib-Derived JAK3 Inhibitors
ƒVƒ“ƒ|ƒWƒXƒg F GEHRINGER MAPFAFFENROT EAFORSTER MABAUER S. MA›LAUFER Stefan

IS01-2
The ƒÐ1 receptor as target for the development of novel drugs
The ƒÐ1 receptor as target for the development of novel drugs
ƒVƒ“ƒ|ƒWƒXƒg F ›WUNSCH Bernhard

ŒŸõƒy[ƒW‚É–ß‚é

TOP‚Ö–ß‚é
ƒvƒ‰ƒCƒoƒV[ƒ|ƒŠƒV[‚ɂ‚¢‚Ä
@Copyright (C) Œö‰vŽÐ’c–@l“ú–{–òŠw‰ï